This Sleazy GLP-1 Prescription Site Is Using Deepfaked "Before-and-After" Photos of Fake Patients, and Running Ads Showing AI-Generated Ozempic Boxes ...

In the cash grab for patients eager to get on GLP-1 weight loss drugs like Ozempic, startups are getting so sloppy that their marketing materials look like unintentional parody. Consider MEDVi, an ...

MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its website, it wants you to join "50,000+ MEDVi patients" who have turned ...

MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its website, it wants you to join "50,000+ MEDVi patients" who have turned to ...

Semaglutide injections are helping you lose weight-but if yours isn't FDA-approved (and a lot of them aren't), it could be ...

Wellness influencer Janelle Rohner has seen the internet’s criticism after revealing she micro-dosed GLP-1 to lose weight. “‘Ozempic is cheating.’ ‘Ozempic is the easy way out ...

About 12% of Americans say they have ever taken a GLP-1 drug, including 6% who say they are currently in treatment. A recent study found that more than half of patients with overweight or obesity ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should continue GLP-1 RAs and adhere to a 1-day clear liquid diet preoperatively.

KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs. KFF. May 10, 2024. Do D et al. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 ...

GLP-1 receptor agonists (GLP-1s) have shown impressive results, with some studies reporting weight reductions of 5 to 18 percent. They also provide metabolic and cardiovascular benefits, a big concern ...

Virta’s 0% GLP-1 utilization trend guarantee, coupled with guaranteed weight loss outcomes, and 1:1 Claims Based ROI are the first of its kind in the industry, reflecting the company’s ...